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Abstract
Background: Microwave ablation (MWA) is increasingly used to achieve local control for liver tumours.
This study sought to examine a monocentric experience with MWA, with a primary hypothesis that
primary tumour histology was a significant predictor of early recurrence.
Methods: Retrospective single-institution review identified consecutive patients with liver tumours
treated by MWA. Cox proportional hazards models assessed significance of prognostic variables.
Results: Seventy-two patients (43 female, 60%) underwent 83 MWA procedures for 157 tumours.
Tumour histologies included hepatocellular cancer (10 operations), colorectal metastases (39), metastatic
carcinoid (20) and other (14). The median tumour size was 2.0 cm. A concomitant liver resection was
performed in 50 cases (60%). Crude peri-operative morbidity and mortality rates were 16% and 1%,
respectively. The median follow-up was 16 months. Ablations were complete for 149 out of 157 tumours
(95%). The median overall and recurrence-free survivals were 36 and 18 months, respectively. There was
no difference in time to recurrence between the primary tumour types. In multivariable models,
recurrence-free survival was independently associated with the use of neoadjuvant [hazard ratio (HR):
2.90, 95% confidence interval (CI): 1.09–7.76, P = 0.034] and adjuvant chemotherapy (HR: 0.36, 95%
CI: 0.15–0.82, P = 0.016).
Conclusions: MWA is a safe and feasible approach for local control of liver tumours. While chemo-
therapy administration was associated with time to recurrence after MWA, larger studies are needed to
corroborate these findings.
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Introduction
Surgical resection is generally considered the gold standard for
potentially curative treatments of liver cancer.1,2 Unfortunately,
many patients with hepatic tumours present with lesions that are
deemed unresectable for a variety of technical, anatomic and
patient-related reasons.3 For example, only 20–25% of patients
with colorectal liver metastases (CLM)4 and 30–35% of patients
with hepatocellular carcinoma (HCC)5 will ultimately undergo a
resection. The available treatment options for unresectable
patients include systemic chemotherapy, ablative techniques,
hepatic artery-directed therapies, external beam radiation therapy
and isolated liver perfusion.4,6–9
Experience with microwave ablation (MWA) for liver tumours
has grown in the last several decades. Initially, the ablation zone
size was limited by a single-antennae approach, and only tumours
2 cm were considered for treatment.10 Eventually, larger lesions
could be treated by repositioning antennae11 or using multiple
antennae simultaneously12 to create larger zones of coagulative
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necrosis. Recent reports suggest that tumours up to 6–9 cm in size
may be managed with MWA.13,14 In comparison to radiofrequency
ablation (RFA), MWA offers theoretical advantages of faster deliv-
ery, a wider zone of active heating, higher intratumoral tempera-
tures and less susceptibility to heat sink when performed near
large vessels.4,13–15 MWA has also been associated with lower
median operating room costs ($13 389 for MWA compared with
$25 687 for RFA).14
Based on a phase II trial13 and large single-centre experience14
from the USA, successful complete tumour ablation can be
achieved for >90% of patients who undergo MWA. Tumour
control at the site of ablation was excellent in these series, with
only 2.7–6.0% of patients recurring locally. Unfortunately, nearly
half the patients recurred at remote hepatic and extrahepatic sites.
Factors that may predispose some patients to recur after MWA
have not been well established. The objective of this study was to
identify the demographic and clinical characteristics that may
predispose patients to early local and/or distant recurrence after
hepatic MWA. The primary hypothesis was that primary tumour
histology was a significant predictor of early recurrence.
Methods
After Institutional Review Board approval, a single-institution ret-
rospective review of all patients with hepatic malignancies who
had been treated with MWA at Froedtert Hospital (Milwaukee,
WI, USA) between July 2007 and June 2011 was performed. Treat-
ment planning for patients with liver tumours is orchestrated
through a weekly multidisciplinary conference of medical oncolo-
gists, radiation oncologists, interventional radiologists, hepatolo-
gists, transplant surgeons and surgical oncologists. This study
encompasses all approaches to MWA (open, laparoscopic and
percutaneous) in addition to including both disciplines of surgery
and interventional radiology.
In addition to standard demographic data, the clinical features
of each patient were collected: histological type of tumour,
tumour diameter, number of tumours, extent of liver tumour
burden (unilateral versus bilateral), presence of background liver
disease, presence of extrahepatic disease, previous treatments
received and adjuvant treatments administered. All operations
were performed with curative intent via an ultrasound-guided16
open or laparoscopic surgical approach (under general anaesthe-
sia) or with a computed tomography (CT)-guided percutaneous
approach (under light sedation). Evident™ MWA Surgical Anten-
nae, Evident™ MWA Pump Tubing and Chambers, Valleylab™
MW Ablation Generators and Valleylab™ MW Ablation Pumps
were used for all procedures (Covidien™, formerly Valleylab™;
Boulder, CO, USA), with the generator set to 45 watts. Typically,
a single antennae application would last 10 min, although the
actual time of application was recorded for each operation. In
some instances, concurrent hepatic and/or extrahepatic resections
were performed, and in these instances the margin status was
recorded.
The Clavien–Dindo17 system was used to classify adverse events
that occurred within 90 days after MWA. Death within 90 days
was considered peri-operative mortality. Recurrence-free survival
(RFS) was the interval from the date of ablation until the date
when either local or distant recurrence was noted, or follow-up
ended. Although not the primary endpoint owing to heterogene-
ous tumour histologies, overall survival (OS) analyses were
included and defined as the interval from the date of ablation until
either the date of death or end of follow-up. All patients had
previous cross-sectional imaging with either contrast-enhanced
CT or magnetic resonance imaging (MRI). Ablations were con-
sidered incomplete if any amount of pre-procedure contrast
enhancement patterns persisted on the immediate post-procedure
CT or MRI, as determined by a dedicated hepatobiliary radiolo-
gist. Thereafter, patients were followed with contrast-enhanced
cross-sectional imaging every 3 months for the first year, and then
biannually. Recurrent disease within 1 cm of the ablation site was
considered a local recurrence.13 Length of stay in the hospital was
calculated by total days; outpatient procedures were considered a
1-day stay. Patients who had incomplete ablation or known
residual disease were excluded from recurrence analysis. OS analy-
sis included all patients.
Statistical analysis
With patients divided into histological groups, descriptive statis-
tics were calculated for all variables. Between-group differences
were tested with Fisher’s exact (categorical variables) and Mann–
WhitneyU-tests (continuous variables). Survival curves were gen-
erated using the Kaplan–Meier method, and compared with the
log-rank test for equality of survivor functions. Cox proportional
hazards models were used to test all demographical and clinico-
pathological variables for independent prognostic significance
with regards to timing of recurrence. Because tumour histology
was the primary variable of interest, it was automatically included
in the final model. Any prognostic factors showing P-values <0.2
on univariate analysis were included in a multivariable model.
Possible variables associated with recurrence from previous
reports of RFA (age, tumor size, and chemotherapy use) were also
included in the final model. Significance was set at a = 0.05. Stata
IC 12 (StataCorp LP, College Station, TX, USA) was used for all
statistical analyses.
Results
Seventy-two patients (38 female, 53%) underwent 83 MWA pro-
cedures. In total, 157 tumours were treated with MWA. Charac-
teristics of the study populations are shown in Table 1 by tumour
type. The cancer histologies in the other malignancies category
were one gastrointestinal stromal tumour, one anal squamous cell
cancer, five breast cancers, one cholangiocarcinoma, one clear
cell carcinoma, one melanoma, two ovarian cancers, one renal cell
carcinoma and one sarcoma. Ablations were relatively uncommon
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Table 1 Characteristics of 83 microwave ablation procedures, by primary tumour type
Variable HCC CLM MC Other cancer Total P-value
n = 10 n = 39 n = 20 n = 14 n = 83
Median age, years (range) 71 (56–88) 62 (38–84) 58 (25–82) 58 (42–76) 60 (25–88) 0.050
Gender, n (%) 0.023
Female 2 14 12 10 38 (46)
Male 8 25 8 4 45 (54)
Descent, n (%) 0.563
Caucasian 7 33 18 13 71 (86)
African-American 3 4 2 1 10 (12)
Hispanic 0 2 0 0 2 (2)
Synchronous, n (%) <0.001
Yes — 30 12 1 43 (61)
No — 9 7 12 28 (39)
Route of ablation, n (%) 0.001
Open 4 34 20 8 66 (80)
Laparoscopic 3 3 0 4 10 (12)
Percutaneous 3 2 0 2 7 (8)
Number of tumours ablated,
n (%)
0.004
1 9 26 6 12 53 (64)
2 1 10 6 1 18 (22)
3 0 3 8 1 12 (14)
Median ablated tumour
size, cm (range)
2.0 (0.9–3.0) 1.5 (1.0–5.5) 1.6 (1.0–5.0) 2.2 (0.9–3.0) 2.0 (0.9–5.5) 0.161
Median no. probe
applications (range)
2 (1–4) 2 (1–8) 2.5 (1–18) 2 (1–6) 2 (1–18) 0.748
Median cumulative ablation
time, min (range)
18 (10–40) 20 (5–70) 20 (5–180) 20 (10–60) 20 (5–180) 0.850
Neoadjuvant chemotherapy,
n (%)
<0.001
Yes 0 33 7 5 45 (54)
No 10 6 13 9 38 (46)
Adjuvant chemotherapy,
n (%)
0.055
Yes 0 15 9 4 28 (34)
No 10 23 11 10 54 (66)
Concomitant hepatectomy,
n (%)
0.227
None 7 13 4 9 33 (40)
Wedge resection/
segmentectomy
2 10 7 2 21 (25)
Sectionectomy 1 9 6 2 18 (22)
Lobectomy 0 7 2 1 10 (12)
Extended lobectomy 0 0 1 0 1 (1)
Extrahepatic disease, n (%) 0.018
None present 9 35 11 12 67 (81)
Present and resected 1 4 8 1 14 (17)
Present, but unresectable 0 0 1 1 2 (2)
HCC, hepatocellular carcinoma; CLM, colorectal liver metastases; MC, metastatic carcinoid.
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for tumours in segments 1–3 because of the largely resectable
nature of this anatomic position (Fig. 1).
The median hospital stay for an open ablation was significantly
longer (6 days, range: 4–34, P < 0.001) than either laparoscopic
(2 days, range: 1–7) or percutaneous ablations (1 day, range: 1–2).
Even when patients who had undergone a concomitant surgical
resection were excluded, these differences in length of stay
remained significant (P < 0.001). All complications (n = 13,
16% morbidity rate) occurred after open ablations, and five com-
plications were grade III or higher. One patient died from rapid
progression of MC 52 days after a complication-free hemihepate-
ctomy and MWA (overall 90-day mortality rate of 1%). The
overall MWA success rate was 95% for curative-intent ablations,
with 8 of 157 tumours incompletely ablated on initial postopera-
tive imaging (all eight from open operations). An additional four
patients with MC had unanticipated miliary disease making a
complete ablation of all disease unfeasible. Between those with
unresectable extrahepatic disease (2 patients), those with incom-
plete ablations (8 patients) and those with untargeted miliary
disease (4 patients), there were 14 patients (17%) who had
persistent disease after MWA.
The median follow-up was 16 months (range: 2–42). The 14
patients with persistent disease after MWA (who had a total of 28
tumors targeted for ablation) were excluded from further RFS
analysis. Of the remaining 129 tumours (82%), there were 10 local
recurrences (8%; all 10 recurrences were from tumors in segments
4–8). Other patterns of recurrence are shown in Table 2. At the end
of follow-up, 22 out of 72 patients (31%) had died. Median, 1-, and
3-year RFS and OS rates for each primary cancer type are shown in
Table 2. Neither RFS (P= 0.407) nor OS (0.862) curves significantly
differed between cancer groups (Fig. 2). In multivariable models,
the primary tumour type (P = 0.961, Table 3) and tumour size (P =
0.402) were not associated with time to recurrence. Younger age (P
= 0.039) and treatment with neoadjuvant chemotherapy (P =
0.034) were independently associated with earlier cancer recur-
rence, whereas treatment with adjuvant chemotherapy (P = 0.016)
was independently associated with a longer time to recurrence.
Discussion
Both technology and molecular understanding of hepatic tumour
biology have improved in recent years. As a result, the number of
treatment options for patients with unresectable tumours contin-
ues to expand. However, published evidence supporting systemic
therapy compared with radiation or various liver-directed thera-
pies for these patients is scarce. MWA is a relatively new thermo-
ablative modality used to provide local control of liver tumours,
and the history of its clinical utility has been thoughtfully outlined
by other authors.13,14,18,19 Ablation has been proposed for several
clinical scenarios: curative intent,2,20 reducing tumour burden,21,22
and bridging to transplantation.23,24 The factors associated with
risk of early recurrence after MWA are not well described, and
are important considerations when selecting patients for such
treatment.
This study found that timing of recurrence after MWA was not
significantly different between primary tumour types. Younger
patients and those treated with neoadjuvant chemotherapy were
at the highest risk for recurrence, whereas adjuvant chemotherapy
given after MWA was independently associated with prolonged
RFS. In similar studies of RFA for CLM, the size and number of
tumours treated have been consistently shown to affect local
recurrence rates;1 however, these associations were not found to be
significant. As experience with MWA grows and larger patient
populations can be studied, other factors associated with early
recurrence may be identified.
In this study, most liver tumours were originally characterized
by contrast-enhanced CT, and the same imaging modality was
therefore used for surveillance. Two patients had liver tumours
initially evident on MRI which were not clearly characterized on
CT, and therefore MRI was used for surveillance. After MWA, all
patients underwent contrast-enhanced cross-sectional imaging
every 3 months for the first year, and biannually thereafter.
Positron emission tomography was not used for surveillance
in this study, and guidelines have not been established recom-
mending its use after ablation.1 To our knowledge, no specific
imaging has shown superior capability to detect recurrence
after thermoablation.
The safety of MWA has been established in previous studies,
with a peri-procedural mortality rate <0.01%.25,26 While one
patient died within 90 days, this was attributed to a aggressive
tumour biology and not a result of ablation. A systematic review
of MWA outcomes suggest that aside from procedural pain and
pyrexia, ascites and biliary complications are among the most
common adverse events.18 Over half of the patients in this study
Figure 1 The number of tumours ablated by a liver segment during
83 microwave ablation procedures (n = 157). Published with permis-
sion from © brysonbiomed.com
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underwent a concomitant hepatectomy, and as other authors have
noted,14,19 attributing morbidity to ablation itself is challenging.
Open operations accounted for all complications, suggesting that
the laparotomy incision and/or transected liver surface represent
the major source of morbidity after ablation. Percutaneous MWA
avoids the need for general anaesthesia, allows for the shortest
hospital stay and for instant feedback on the success of ablation.
Small-volume disease, particularly on the liver capsule, may not be
appreciated with a percutaneous approach. As a result of anatomic
factors, some lesions are difficult to reach percutaneously. Lapar-
oscopy and open surgery allow for gross hepatic inspection and
the use of intra-operative ultrasound, which may find unantici-
pated lesions in up to 10–20% of operations.27
Some limitations of this study warrant attention. Methodologi-
cally, MWA was performed on heterogeneous tumour histologies
for non-uniform indications. A concurrent hepatectomy may
influence outcomes after thermoablation, and the interrelation-
ship between such simultaneous treatments has not been well
established. Some late recurrences may not have been appreciated
because of a short follow-up interval. Although the low number
of purely local recurrences is encouraging, it limits a rigorous
statistical investigation. Therefore, future studies with larger
numbers of tumours will be needed to better understand the
clinical factors that may specifically predispose patients to local
failure after MWA.
In conclusion, this study finds that MWA for liver malignancies
offers a local recurrence rate of 8% and a median RFS of 18
months. The durability of local control did not vary significantly
between primary tumour types. Younger patients and patients
with larger tumours were found to be at an increased risk for early
recurrence, which should be thoughtfully considered when MWA
is proposed for the treatment of liver tumours. The safety profile
Table 2 Outcomes of 83 microwave ablation procedures, by primary tumour type
Variable HCC CLM MC Other cancer Total P-value
n = 10 n = 39 n = 20 n = 14 n = 83
Complete ablation, n (%) 0.006
Yes 9 38 14 14 75 (90)
No 1 1 6 0 8 (10)
No. patients with
complication, n (%)
0.747
No complication 8 34 16 12 70 (84)
Grade 1–2 1 3 3 1 8 (10)
Grade 3 1 2 1 1 5 (6)
Median hospital stay, days
(range)
2 (1–11) 6 (1–34) 6 (5–24) 5 (1–7) 5 (1–34) 0.003
Recurrence, n (%) 0.039
Persistent disease after
ablation
1 3 9 1 14 (17)
No recurrence 6 15 3 8 32 (39)
Recurrence at ablation
site only
1 6 2 1 10 (12)
Remote hepatic
recurrence only
1 7 6 3 17 (20)
Extrahepatic recurrence
only
0 3 0 1 4 (5)
Intra- and extrahepatic
recurrence
1 5 0 0 6 (7)
Recurrence-free survival 0.407
Median, months NR 10.9 24.4 17.9 18.1
1-year, % 59 47 76 58 59
3-year, % NR 0 29 29 14
Overall survival 0.862
Median, months NR 36.1 33.0 NR 36.1
1-year, % 83 92 94 100 95
3-year, % NR 35 43 75 41
HCC, hepatocellular carcinoma; CLM, colorectal liver metastases; MC, metastatic carcinoid; NR, not reached.
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for MWA itself is excellent, with open operations accounting for
all morbidity in this series. Given that each route of ablation offers
certain benefits and drawbacks, further study is needed to address
the comparative long-term benefit of open, laparoscopic and
percutaneous MWA.
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